Form 4: Regeneron Director Arthur F. Ryan Disposes of Shares Under 10b5-1 Plan
SEC Form 4
Director Arthur F. Ryan sold shares of Regeneron Pharmaceuticals, Inc. on July 1, 2024, under a pre-arranged 10b5-1 trading plan.
Summary
- On July 1, 2024, Arthur F. Ryan, a director of Regeneron Pharmaceuticals, Inc., disposed of shares of common stock.
- The sales were executed under a Rule 10b5-1(c) trading plan adopted on August 7, 2023.
- A total of 93 shares were sold in multiple transactions at prices ranging from $1,047.11 to $1,068.09.
- Following the reported transactions, Ryan directly owns 17,882 shares of Regeneron common stock.
Sentiment
Score: 5
Explanation: The document is a routine disclosure of stock sales by a company director under a pre-arranged trading plan. It doesn't inherently indicate positive or negative sentiment about the company's prospects.
Industry Context
Sales by insiders are a common occurrence and are often pre-planned to avoid accusations of trading on inside information. The use of a 10b5-1 plan provides a legal framework for insiders to sell shares at predetermined times and prices.
Stakeholder Impact
- The sale of shares by a director could be perceived negatively by some shareholders, but the existence of a 10b5-1 plan mitigates concerns about insider trading.
Key Dates
| Date | Description |
|---|---|
| 2023-08-07 | Date of adoption of the Rule 10b5-1(c) trading plan |
| 2024-07-01 | Date of the reported transactions (sale of shares) |
| 2024-07-02 | Date of signature of the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.